Notable
AIM-IBD · Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative Colitis
Primary completion pushed from May 30, 2027 to Dec 30, 2027
Also in this update: Trial status changed: Recruiting → Not Yet Recruiting; Study completion pushed from Nov 30, 2027 to Apr 30, 2028
ENBIOSIS BIOTECHNOLOGIESNot applicable NCT07619638 Registry history of NCT07619638 on ClinicalTrials.gov (opens the registry)